uploads/2018/01/MDXGanalysts-Reco-1.png

MiMedx Group on the Street: Analyst Recommendations in January

By

Updated

MDXG: a company overview

MiMedx Group (MDXG) operates in the regenerative biomaterials segment. The company is an integrated developer, marketer, and processor of proprietary regenerative products processed from human placental tissue, skin, and bone.

MiMedx is a leading global supplier of amniotic tissue products and has supplied over a million allografts in wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry.

Article continues below advertisement

MDXG’s analyst recommendations

Of the four analysts covering MiMedx Group in January 2018, three have given the stock a “buy” rating, and one analyst has given it a “strong buy” rating. The mean rating for the stock is 1.75, with a target price of $19.

Notably, MiMedx Group makes up about 0.15% of the iShares Russell 2000 Growth ETF’s (IWO) total portfolio holdings.

Peer ratings

By comparison, of the eight analysts covering Atricure (ATRC) in January 2018, seven analysts have given the company a “buy” or a higher rating, while only one analyst has given it a “hold” rating. The mean rating for the stock is 1.75, with a target price of $24.43.

Of the 13 analysts covering Globus Medical (GMED) in January 2018, seven analysts have given the stock a “buy” or a higher rating. Five analysts have given it a “hold” rating, while only one analyst has given the stock a “sell” rating. The mean rating for the stock is 2.23, with a target price of $45.33.

Of the six analysts covering Inogen (INGN) in January 2018, four analysts have given the stock a “buy” or a higher rating, while the remaining two analysts have given it a “hold” rating. The mean rating for the stock is 1.83, with a target price of $117.

In the next part of this series, we’ll take a look at the distribution agreements entered into by MiMedx Group that are aimed at driving sales.

Advertisement

More From Market Realist